» Articles » PMID: 7811047

Emerging in Vitro Resistance to Quinolones in Penicillinase-producing Neisseria Gonorrhoeae Strains in Hawaii

Overview
Specialty Pharmacology
Date 1994 Sep 1
PMID 7811047
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The susceptibilities of 37 penicillinase-producing strains of Neisseria gonorrhoeae (PPNG), isolated in Hawaii from December 1991 through January 1994, were determined to ciprofloxacin and ofloxacin, fluoroquinolone agents currently recommended by the Centers for Disease Control and Prevention as alternative regimens for the treatment of uncomplicated gonorrhea. Nine isolates (24.3%) exhibited decreased susceptibilities (MICs, > or = 0.06 microgram/ml) to ciprofloxacin and ofloxacin. Ciprofloxacin MICs for three isolates (8.1%) were 2.0 micrograms/ml; these isolates belonged to the auxotype/serovar class Pro/IB-7 and possessed the 3.2-MDa beta-lactamase and the 24.5-MDa conjugative plasmids. Six strains for which ciprofloxacin MICs were 0.06 to 0.125 microgram/ml belonged to a variety of gonococcal phenotypes. Strains for which ciprofloxacin MICs were 2.0 micrograms/ml were isolated from persons who had traveled to, or were sexual contacts of persons who had recently traveled to, Southeast Asia. Persons infected with these isolates had been treated with ceftriaxone (250 mg intramuscularly, single dose); therefore, none of these cases were associated with clinical failure following the use of fluoroquinolone therapy. Further studies are needed to confirm the clinical and public health significance of increased in vitro resistance to ciprofloxacin and ofloxacin in N. gonorrhoeae.

Citing Articles

Safety Aspects and Rational Use of Single Intramuscular Dose Ceftriaxone: Clinical Insights on the Management of Uncomplicated Gonococcal Infections.

Allen G, Morrill H Drug Healthc Patient Saf. 2023; 15:159-170.

PMID: 37941731 PMC: 10629349. DOI: 10.2147/DHPS.S350763.


Emerging Trends in Antibiotic Resistant Neisseria gonorrhoeae: A National and Hawai'i Perspective.

Katz A, Komeya A, Dewater J, Tomas J, Chinna L, Wasserman G Hawaii J Health Soc Welf. 2020; 79(3):68-70.

PMID: 32190837 PMC: 7061027.


Epidemiology of gonorrhoea: a global perspective.

Kirkcaldy R, Weston E, Segurado A, Hughes G Sex Health. 2019; 16(5):401-411.

PMID: 31505159 PMC: 7064409. DOI: 10.1071/SH19061.


Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016.

Katz A, Komeya A, Kirkcaldy R, Whelen A, Soge O, Papp J Clin Infect Dis. 2017; 65(6):918-923.

PMID: 28549097 PMC: 6748320. DOI: 10.1093/cid/cix485.


Antimicrobial Resistance in Neisseria gonorrhoeae.

Kidd S, Kirkcaldy R, Burstein G Adolesc Med State Art Rev. 2016; 25(2):316-31.

PMID: 27132316 PMC: 6749829.


References
1.
SHORT H, Ploscowe V, Weiss J, Young F . Rapid method for auxotyping multiple strains of Neisseria gonorrhoeae. J Clin Microbiol. 1977; 6(3):244-8. PMC: 274747. DOI: 10.1128/jcm.6.3.244-248.1977. View

2.
Knapp J, Tam M, Nowinski R, Holmes K, Sandstrom E . Serological classification of Neisseria gonorrhoeae with use of monoclonal antibodies to gonococcal outer membrane protein I. J Infect Dis. 1984; 150(1):44-8. DOI: 10.1093/infdis/150.1.44. View

3.
Morse S, Johnson S, Biddle J, Roberts M . High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant. Antimicrob Agents Chemother. 1986; 30(5):664-70. PMC: 176510. DOI: 10.1128/AAC.30.5.664. View

4.
Gorwitz R, Nakashima A, Moran J, Knapp J . Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae--United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ. 1993; 42(3):29-39. View

5.
Tapsall J, Shultz T, Lovett R, Munro R . Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea. Med J Aust. 1992; 156(2):143. DOI: 10.5694/j.1326-5377.1992.tb126457.x. View